7 June 2019
Gene therapy dominated haemophilia B pipeline may see long-term benefits
Treatments for haemophilia B have been focused on replacing the missing or deficient FIX levels.
Focus:
Comment
-
7 June 2019
Sanofi offers more convenient delivery in multiple myeloma treatment with Isatuximab
MM patients have the opportunity to choose between two equally effective treatment options and various modes of administration that can better serve their needs and preferences.
-
7 June 2019
Pfizer’s Phase III trial of Lyrica in PGTC seizures falls short of endpoint
Primary generalised tonic-clonic (PGTC) is a chronic disorder involving recurrent seizures in both adults and children.
-
6 June 2019
Landmark study shows pharma worse than the automotive industry for carbon emissions
In addition to the lack of awareness of pharma’s contribution to climate change, lack of adequate regulation is a key contributing factor.
-
6 June 2019
Amgen unveils promising data in KRAS G12C non-small cell lung cancer
KRAS is a long sought after target in the oncology R&D space and has thus far proven to be undruggable.
-
6 June 2019
Novel biologics are on the horizon for EGFR-mutated non-small cell lung cancer
Despite being preliminary, these results are promising for a high unmet need patient group.
-
6 June 2019
AbbVie shoots for AAN 2020 target readout for Phase II MS trials at current enrolment rate
Source says AbbVie will present data about its Phase II trials of ABT-555 at AAN 2020. AbbVie's official press office declined to comment on the story.
-
6 June 2019
Novartis denies physicians’ reports of Mayzent launch delays
A Novartis spokesperson said there are no known access delays to patients who are prescribed Mayzent, and many patients have already initiated the onboarding to Mayzent efficiently.
-
5 June 2019
Long-awaited novel therapies for ovarian cancer have arrived
GlobalData anticipates that the clinical development efforts to diversify available therapies in ovarian cancer will push novel targeted therapies and immunotherapies into the market.
-
5 June 2019
As small molecules continue to dominate industry approvals, API manufacturing rises in importance
64% of New Molecule Entity approvals by European and US authorities in 2018 were for small molecule drugs, according to GlobalData.